-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4255 Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical trials, Acute Myeloid Malignancies, AML, Combination therapy, Adult, Drug development, Elderly, Clinical Research, Diseases, Treatment Considerations, Myeloid Malignancies, Study Population, Human
Monday, December 9, 2024, 6:00 PM-8:00 PM

Naval Daver, MD1, Kyoo Hyung Lee, MD, PhD2*, Yunsuk Choi, MD, PhD2, Pau Montesinos, PhD, MD3*, Brian A. Jonas, MD, PhD4, Martha L. Arellano, MD5, Uma Borate, MD6, Justin M. Watts, MD7, Paul B. Koller, MD8, Chul Won Jung, MD9, Sang Kyun Sohn10*, Amir T. Fathi, MD11, Pankit Vachhani, MD12*, Nikolai A. Podoltsev, MD, PhD13, Olga Salamero, MD14*, Sung-Soo Yoon, M.D., Ph.D.15, Jeong-Ok Lee, MD16, Gabriel N Mannis, MD17, Shuhying Tan, FRACP, FRCPA, MBBS18*, Sudipto Mukherjee, MD, PhD, MPH19, Harry Erba, MD, PhD20*, Ho-Jin Shin, MD21*, Uwe Platzbecker, MD22, Mar Tormo, MD23, Eric Tam, MD24, Leanne Berkahn, MD25, Teresa Bernal26*, Donna Nguyen Haney27*, Jia Hu, PhD27*, Ranjeet Kumar Sinha, PhD27*, Nawazish Khan, MD, MS27*, Vivian Costa Victory, PhD27*, William G. Rice, PhD27 and Rafael Bejar, MD, PhD27

1University of Texas MD Anderson Cancer Center, Houston, TX
2Asan Medical Center, Seoul, Korea, Republic of (South)
3Hematology, Hospital Universitari I Politécnic La Fe and Programa Español de Tratamientos en Hematología (PETHEMA) Group, Valencia, Spain
4UC Davis Comprehensive Cancer Center, Davis, CA
5Emory University, Atlanta, GA
6The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
7University of Miami, Miller School of Medicine, Miami, FL
8Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
9Samsung Medical Center, Seoul, South Korea, KOR
10Kyungpook National University Hospital, Daegu, Korea, Republic of (South)
11Massachusetts General Hospital, Boston, MA
12University of Alabama at Birmingham, Birmingham, AL
13Yale School of Medicine, New Haven, CT
14Hematology Department, University Hospital Vall d’Hebron, Barcelona, Spain
15Center for Medical Innovation, Seoul National University Hospital, Seoul, Korea, Republic of (South)
16Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South)
17Stanford, Stanford Cancer Center, Palo Alto, CA
18St. Vincent's Hospital, Melbourne, Australia
19Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
20Duke Cancer Institute, Durham, NC
21Pusan National University Hospital, Busan, Korea, Republic of (South)
22Hematology and Cellular Therapy, University of Leipzig Medical Center, Leipzig, Germany
23INCLIVA Research Institute, University Clinical Hospital, Valencia, Spain
24USC Norris Comprehensive Cancer Center, Los Angeles, CA
25Aukland City Hospital, Auckland, New Zealand
26Hospital Universitario Central de Asturias, Oviedo, Spain
27Aptose Biosciences, San Diego, CA

INTRODUCTION: Combination therapy with a hypomethylating agent (HMA) and venetoclax (VEN) has improved response rates and overall survival of newly diagnosed AML patients. However, long-term outcomes remain poor, particularly in those with adverse clones harboring FLT3-ITD, RAS, or TP53 mutations. Since the emergence of VEN resistance is associated with a dismal prognosis, addition of a well-tolerated and active agent to the HMA/VEN combination is needed to improve response rates, increase survival, and prevent emergence of resistant AML clones.

Tuspetinib (TUS) is a potent once daily oral kinase inhibitor of SYK, FLT3, JAK1/2, RSK1/2, mutant KIT, and TAK1-TAB1 kinases that mediate dysregulated cellular proliferation in AML. Development of TUS as a combination agent with HMA/VEN is supported by early phase safety and efficacy results in R/R AML, both as a monotherapy and in combination with VEN.

AIMS: To assess the safety, tolerability, and pharmacokinetics (PK) of TUS and TUS/VEN to support selection of appropriate doses for monotherapy and combination (doublet and triplet) therapy.

METHODS: TUS was administered to study participants (pts) with R/R AML as a single agent in dose escalation, exploration, and expansion (20–200 mg once daily dose levels), and at once daily dose levels of 40 and 80 mg in combination with VEN (400 mg once daily dose). Cycles were planned to be 28 days, with a C1D15 marrow assessment in the combination arm.

RESULTS: As of July 02, 2024, 93 pts have been treated with TUS monotherapy: pts were mostly Asian (47.3%) and White (41.9%) with a median age of 63 years (range 18–84 years). No TUS-related non-hematologic SAEs, QTc prolongation, differentiation syndrome, deaths, or discontinuations were observed. Clinical responses with TUS were observed across the 40–160 mg dose levels including the recommended Phase 2 dose of 80 mg (n=19, CRc=26.3%) among all evaluable pts. Clinical response was superior in VEN-naïve (n=30, CRc=30.0%) vs prior-VEN treated pts (n=35, CRc=5.7%), with CR/CRh=35.7% (n=14) for VEN-naïve pts receiving 80 mg TUS. Among pts with FLT3 mutated (FLT3-MUT) treated with TUS 80 mg, CRc=37.5% (n=8), with 33.3% (n=3) in prior-FLT3i exposed. Dose cohorts higher than 80 mg TUS had a greater proportion of prior-VEN treated pts, which likely impacted their response rate, motivating study of the TUS/VEN combination.

Seventy-nine pts were treated with TUS/VEN combination therapy: pts were largely White (77.2%) with a median age of 69 years (range 31–86 years); with 73.4% having wild-type FLT3 (FLT3-WT). Participants received a mean of 2.3 prior lines of therapy (range 1–7); 74.7% were prior-VEN treated. The most frequent TEAEs were those typically associated with VEN, including febrile neutropenia (26.6%; lower than expected for a VEN-containing regimen in R/R AML), nausea (26.6%), and pneumonia (22.8%). Objective responses were observed (overall CRc=18.5%) in pts receiving 80 mg TUS/400 mg VEN: FLT3-WT (n=49, CRc=16.3%); FLT3-MUT (n=15, CRc=26.7%), including pts with prior-FLT3i treatment (n=13, CRc=30.8%); prior-VEN treated (n=48, CRc=18.8%); and VEN-naïve (n=17, CRc=17.6%) pts. One response (n=14; 7.1%) was observed at 40 mg TUS/400 mg VEN. PK data showed no clinically meaningful interactions between TUS and VEN. Available data from the frontline triplet study will be presented at the meeting.

CONCLUSIONS: Tuspetinib as monotherapy and in combination with VEN has been well- tolerated with objective responses among diverse AML patient groups including those with FLT3-WT and mutated TP53 or RAS, and in prior-VEN and prior-FLT3i treated pts. These safety and efficacy results support the upcoming combination of TUS/VEN plus azacitidine as a triplet in newly diagnosed AML pts ineligible for intensive chemotherapy, independent of FLT3 mutation status.

Disclosures: Daver: Astellas: Consultancy, Research Funding; Menarini Group: Consultancy; Hanmi: Research Funding; Novartis: Consultancy; Jazz: Consultancy; Celgene: Consultancy; Novimmune: Research Funding; Syndax: Consultancy; Trillium: Consultancy, Research Funding; Agios: Consultancy; Shattuck Labs: Consultancy; KITE: Research Funding; Trovagene: Research Funding; Arog: Consultancy; Glycomimetics: Research Funding; FATE Therapeutics: Other: Consulting Fees, Research Funding; Genentech: Consultancy, Research Funding; Servier: Consultancy, Research Funding; Gilead: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Daiichi-Sankyo: Consultancy, Research Funding. Montesinos: Janssen: Membership on an entity's Board of Directors or advisory committees, Other: research support, Speakers Bureau; Daiichi Sankyo, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: research support, Research Funding, Speakers Bureau; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: research support, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: research support, Research Funding, Speakers Bureau; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: research support, Research Funding, Speakers Bureau; Jazzpharma: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; Novartis: Consultancy, Research Funding, Speakers Bureau; Kura Oncology: Consultancy; Syndax: Consultancy; Glycomimetics: Consultancy. Jonas: Incyte: Research Funding; Immune-Onc: Research Funding; Hanmi: Research Funding; Forty-Seven: Research Funding; Forma Therapeutics: Research Funding; F. Hoffman-La Roche: Research Funding; Celgene: Research Funding; Aptose: Research Funding; AROG: Research Funding; Amgen: Research Funding; Rigel: Consultancy, Other: Travel; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kymera: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlycoMimetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Research Funding; Loxo Oncology: Research Funding; Pharmacyclics: Research Funding; Sigma Tau: Research Funding; Treadwell: Research Funding. Arellano: Syndax Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees, Other: Advisory board meeting 5/31/24, Syndax pharmaceuticals, role of menin inhibition in treatment of acute leukemias. Borate: Vincerx Pharma: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy; Sumitomo: Consultancy; Rigel: Consultancy; Novartis: Consultancy; Astellas: Consultancy; Abbvie: Consultancy; BMS: Consultancy; Takeda: Other: IDMC; Beigene: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy. Watts: Takeda: Research Funding; Immune Systems Key: Research Funding; Rafael Pharma: Consultancy; Reven Pharma: Consultancy; Daiichi Sankyo: Consultancy; Aptose: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; Celgene/BMS: Consultancy; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Rigel: Consultancy, Other: safety monitoring or advisory boards, Research Funding. Koller: Ascentage: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Travel, Speakers Bureau. Jung: GSK: Honoraria. Fathi: Mablytics: Consultancy; Kite: Consultancy; Autolus: Consultancy; Ispen: Consultancy; Gilead: Consultancy; AbbVie, BMS/Celgene, and Agios/Servier: Research Funding; Pfizer: Consultancy; Abbvie: Consultancy, Research Funding; Menarini Group: Consultancy; Ipsen: Consultancy; EnClear: Consultancy; AstraZeneca: Honoraria; Amgen: Consultancy; Genentech: Honoraria; Remix: Consultancy; Rigel: Consultancy; MorphoSys: Consultancy; PureTech: Consultancy; Foghorn, Blueprint Medicines, Kura, Trillium: Honoraria; Takeda: Consultancy; Astellas: Consultancy; ImmunoGen: Consultancy; Novartis: Consultancy; Orum: Consultancy; BMS/Celgene: Consultancy; Agios: Ended employment in the past 24 months; Servier: Consultancy, Research Funding; Daiichi Sankyo: Consultancy; Forma: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding. Vachhani: Daiichi Sankyo: Consultancy; Stemline: Consultancy; Gilead/Forty Seven: Research Funding; Blueprint Medicines: Consultancy, Research Funding; GlaxoSmith Kline: Consultancy; Novartis: Consultancy; Karyopharm: Consultancy; Cogent Biosciences: Consultancy; Amgen: Consultancy, Research Funding; Constellation Pharmaceuticals: Research Funding; Astex Pharmaceuticals: Research Funding; GenenTech: Consultancy; Seattle Genetics: Research Funding; Takeda: Research Funding; Pfizer: Consultancy; CTI BioPharma Corp (now Sobi): Consultancy, Research Funding; Kartos Therapeutics: Research Funding; MorphoSys: Consultancy; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding. Podoltsev: Celgene: Research Funding; Astex Pharmaceuticals: Research Funding; Pfizer: Research Funding; Genentech: Research Funding; Jazz Pharmaceuticals: Research Funding; AI Therapeutics: Research Funding; PharmaEssentia: Consultancy, Honoraria, Research Funding; CTI BioPharma/Sobi: Consultancy, Honoraria, Research Funding; Samus Therapeutics: Research Funding; Daiichi Sankyo: Research Funding; Constellation pharmaceuticals/MorphoSys: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria; Aptose Biosciences: Consultancy, Honoraria, Research Funding; Karyopharm Therapeutics: Consultancy, Honoraria, Research Funding; Cogent Biosciences: Honoraria, Other: IDMC; Boehringer Ingelheim: Research Funding; Arog Pharmaceuticals: Research Funding; Astellas Pharma: Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria; Kartos Therapeutics: Research Funding; Sunesis Pharmaceuticals, Inc.: Research Funding; MorphoSys: Research Funding; Blueprint Medicines: Consultancy, Honoraria. Salamero: Astellas, Jazz, BMS: Consultancy; Jazz, Abbvie: Honoraria. Yoon: Janssen: Honoraria; F. Hoffmann-La Roche Ltd, Genentech, Inc.: Research Funding; Janssen, Novartis, F. Hoffmann-La Roche Ltd, Genentech, Inc.: Consultancy. Mannis: Astex: Research Funding; Genentech: Membership on an entity's Board of Directors or advisory committees; Orbital Therapeutics: Membership on an entity's Board of Directors or advisory committees; Immunogen: Membership on an entity's Board of Directors or advisory committees; Forty Seven: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Research Funding; Astellas: Membership on an entity's Board of Directors or advisory committees; Stemline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Syndax Pharmaceuticals, Inc.: Research Funding; Aptose: Research Funding; Gilead: Research Funding; Rigel: Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Wugen: Membership on an entity's Board of Directors or advisory committees; ImmuneOnc: Research Funding; Glycomimetics: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy; Macrogenics: Consultancy. Erba: AbbVie: Consultancy, Honoraria, Other: Chair, Independent Review Committee for VIALE A and VIALE C, Research Funding; Astellas: Consultancy, Other: Advisory Board; Celgene: Consultancy, Other: Advisory Board; Chair, Myeloid Neoplasms Repository Study., Research Funding, Speakers Bureau; Incyte: Consultancy, Other: Advisory Board/Consultant; Pfizer: Consultancy, Other: Advisory Board/Consultant; Novartis: Consultancy, Other: Advisory Board/Consultant, Research Funding, Speakers Bureau; Macrogenics: Consultancy, Other: Advisory Board/Consultant, Research Funding; Kura Oncology: Consultancy, Other: Advisory Board/Consultant, Research Funding; Jazz: Consultancy, Other: Advisory Board/Consultant, Speakers Bureau; Immunogen: Consultancy, Other: Advisory Board/Consultant; Glycomimetics: Consultancy, Other: Advisory Board; Steering Committee member, Research Funding; Genentech: Consultancy, Other: Advisory Board; Daiichi Sankyo: Consultancy, Other, Research Funding; BMS: Consultancy, Other: Advisory Board; Chair, Myeloid Neoplasms Repository Study., Speakers Bureau; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Schrodinger: Consultancy, Other: Advisory Board/Consultant; Servier: Consultancy, Other: Advisory Board/Consultant, Research Funding, Speakers Bureau; Stemline: Consultancy, Other: Advisory Board/Consultant; Sumitomo Pharma: Consultancy, Other: Advisory Board/Consultant, Research Funding; Syros: Consultancy, Other: Advisory Board/Consultant; Takeda: Consultancy, Other: Advisory Board/Consultant; Trillium: Consultancy, Other: Advisory Board/Consultant; ALX Oncology: Research Funding; Aptose: Research Funding; Ascentage: Research Funding; Oryzon: Research Funding; PTE: Research Funding; Taiho Oncology: Research Funding. Platzbecker: Amgen: Consultancy, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; MDS Foundation: Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Research Funding; Curis: Consultancy, Honoraria, Research Funding; Geron: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Novartis: Consultancy, Research Funding. Tormo: SOBI: Other: Data Safety Monitoring Board; Janssen, AbbVie, Jazz: Other: Travel grant for attending meetings; AbbVie, Gilead, Pfizer, Astellas, BMS: Honoraria. Haney: Aptose Biosciences: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Hu: Aptose Biosciences: Ended employment in the past 24 months. Sinha: Aptose Biosciences: Ended employment in the past 24 months. Khan: Aptose Biosciences: Ended employment in the past 24 months. Victory: Aptose Biosciences: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company; Bristol Myers Squibb: Ended employment in the past 24 months; Turning Point Therapeutics: Ended employment in the past 24 months. Rice: Aptose Biosciences: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees. Bejar: Aptose Biosciences: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company.

OffLabel Disclosure: The approved combination of venetoclax plus azacitidine for the treatment of patients with newly diagnosed AML who are ineligible for intensive chemotherapy will be administered in combination with the investigational medicinal product tuspetinib.

See more of: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III
See more of: Oral and Poster Abstracts
Previous Abstract | Next Abstract >>
*signifies non-member of ASH